Madrigal Pharmaceuticals
MDGL
68 hedge funds and large institutions have $9.88M invested in Madrigal Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 75 → 68 (-7)
39% less capital invested
Capital invested by funds: $16.3M → $9.88M (-$6.43M)
57% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 30
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$330K |
| 2 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$57.5K |
| 3 |
SG Americas Securities
New York
|
+$35.5K |
| 4 |
Citigroup
New York
|
+$11.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$10.7K |
Top Sellers
MDGL Hedge Fund Activity: Q1 2016 in Review
68 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2016, worth a combined $9.88M — down 39% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MDGL and 5 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 13 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $330K. The largest seller was Anson Funds Management, exiting entirely with an estimated $348K sold.
- 68 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2016, down from 75 in Q4 2015.
- Funds reported $9.88M of Madrigal Pharmaceuticals stock for Q1 2016, down 39% quarter-over-quarter.
- 5 funds opened new Madrigal Pharmaceuticals positions in Q1 2016 and 12 closed out, a net change of -7 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $330K added.
- The largest Madrigal Pharmaceuticals seller in Q1 2016 was Anson Funds Management, an estimated $348K sold.
Based on aggregated 13F filings for Q1 2016.